The Omicron variant was first reported to the World Health Organization (WHO) from South Africa on November 24, 2021; this variant is spreading rapidly worldwide. No study has conducted a spatiotemporal analysis of the morbidity of Omicron infection at the country level; hence, to explore the spatial transmission of the Omicron variant among the 220 countries worldwide, we aimed to the analyze its spatial autocorrelation and to conduct a multiple linear regression to investigate the underlying factors associated with the pandemic. This study was an ecological study. Data on the number of confirmed cases were extracted from the WHO website. The spatiotemporal characteristic was described in a thematic map. The Global Moran Index (Moran's I) was used to detect the spatial autocorrelation, while the local indicators of spatial association (LISA) were used to analyze the local spatial correlation characteristics. The joinpoint regression model was used to explore the change in the trend of the Omicron incidence over time. The association between the morbidity of Omicron and influencing factors were analyzed using multiple linear regression. This study was an ecological study. Data on the number of confirmed cases were extracted from the WHO website. The spatiotemporal characteristic was described in a thematic map. The Global Moran Index (Moran's I) was used to detect the spatial autocorrelation, while the LISA were used to analyze the local spatial correlation characteristics. The joinpoint regression model was used to explore the change in the trend of the Omicron incidence over time. The association between the morbidity of Omicron and influencing factors were analyzed using multiple linear regression. The value of Moran's I was positive (Moran's I = 0.061, Z-score = 3.772, p = 0.007), indicating a spatial correlation of the morbidity of Omicron at the country level. From November 26, 2021 to February 26, 2022; the morbidity showed obvious spatial clustering. Hotspot clustering was observed mostly in Europe (locations in High-High category: 24). Coldspot clustering was observed mostly in Africa and Asia (locations in Low-Low category: 32). The result of joinpoint regression showed an increasing trend from December 21, 2021 to January 26, 2022. Results of the multiple linear regression analysis demonstrated that the morbidity of Omicron was strongly positively correlated with income support (coefficient = 1.905, 95% confidence interval [CI]: 1.354-2.456, p < 0.001) and strongly negatively correlated with close public transport (coefficient = -1.591, 95% CI: -2.461 to -0.721, p = 0.001). Omicron outbreaks exhibited spatial clustering at the country level worldwide; the countries with higher disease morbidity could impact the other countries that are surrounded by and close to it. The locations with High-High clustering category, which referred to the countries with higher disease morbidity, were mainly observed in Europe, and its adjoining country also showed high spatial clustering. The morbidity of Omicron increased from December 21, 2021 to January 26, 2022. The higher morbidity of Omicron was associated with the economic and policy interventions implemented; hence, to deal with the epidemic, the prevention and control measures should be strengthened in all aspects.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544667 | PMC |
http://dx.doi.org/10.1002/jmv.28013 | DOI Listing |
IJID Reg
March 2025
Laboratory of Respiratory Viruses, Exanthematous and Enteroviruses and Viral Emergencies, Oswaldo Cruz Institute, Rio de Janeiro, Brazil.
Unlabelled: The SARS-CoV-2 JN.1 lineage emerged in late 2023 and quickly replaced the XBB lineages, becoming the predominant Omicron variant worldwide in 2024. We estimate the epidemiologic impact of this SARS-CoV-2 lineage replacement in Brazil and we further assessed the cross-reactive neutralizing antibody (NAb) responses in a cohort of convalescent Brazilian patients infected during 2023.
View Article and Find Full Text PDFFront Public Health
January 2025
School of Public Health, Peking University, Beijing, China.
Objectives: Besides physical health risks, large public health events also exert negative impacts on people's mental health. We aimed to explore the prevalence and correlates of mental distress and its association with psychological resilience among countries amid the Omicron wave.
Methods: We conducted cross-sectional surveys simultaneously in China and South Korea from March 15 to 30, 2023.
Eur J Public Health
January 2025
Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.
Marketing authorization holders of vaccines typically need to report brand-specific vaccine effectiveness (VE) to the regulatory authorities as part of their regulatory obligations. COVIDRIVE (now id. DRIVE) is a European public-private partnership for respiratory pathogen surveillance and studies of brand-specific VE with long-term follow-up.
View Article and Find Full Text PDFJ Biomed Inform
January 2025
School of Public Health, Zhejiang University School of Medicine, Hangzhou 310058 China; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Electronic address:
Objective: Current studies leveraging social media data for disease monitoring face challenges like noisy colloquial language and insufficient tracking of user disease progression in longitudinal data settings. This study aims to develop a pipeline for collecting, cleaning, and analyzing large-scale longitudinal social media data for disease monitoring, with a focus on COVID-19 pandemic.
Materials And Methods: This pipeline initiates by screening COVID-19 cases from tweets spanning February 1, 2020, to April 30, 2022.
Commun Med (Lond)
January 2025
URC EST, Sorbonne Université, Paris, France.
Background: We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to booster response of vaccinees who received mRNA MV ancestral strain BNT162b2 vaccine (Pfizer-BioNTech).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!